Optimate
https://www.southampton.ac.uk/ctu/trialportfolio/listoftrials/optimate.page Add to Contact List

The OptiMATe trial is investigating whether a two-step optimisation approach to remission induction therapy with MATRix can reduce toxicity and treatment burden, enabling more patients with PCNSL to proceed to HDT-ASCT and improve survival outcomes. As part of the study, original diagnostic FFPE tumour blocks are collected for central pathology review and extraction of DNA and RNA. CSF samples are collected at baseline for extraction of ctDNA. Further samples will only be collected if there is a positive CSF cytology at baseline. ctDNA blood samples are also collected at 5 different time-points throughout the study (at baseline, during trial treatment and at relapse/progression, if applicable).

Contact Information

Last Updated: 05/15/2024

Annual Statistics